These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 1714250)
1. Determination of covalent binding to intact DNA, RNA, and oligonucleotides by intercalating anticancer drugs using high-performance liquid chromatography. Studies with doxorubicin and NADPH cytochrome P-450 reductase. Cummings J; Bartoszek A; Smyth JF Anal Biochem; 1991 Apr; 194(1):146-55. PubMed ID: 1714250 [TBL] [Abstract][Full Text] [Related]
2. Enhancement of doxorubicin toxicity following activation by NADPH cytochrome P450 reductase. Bartoszek A; Wolf CR Biochem Pharmacol; 1992 Apr; 43(7):1449-57. PubMed ID: 1567469 [TBL] [Abstract][Full Text] [Related]
3. Studies on covalent binding of (-)trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene metabolites to cytochromes P-450 LM2 and LM4 and NADPH-cytochrome P-450 reductase. Deutsch J; Vatsis KP; Leutz JC; Coon MJ; Gelboin HV Xenobiotica; 1989 Dec; 19(12):1421-35. PubMed ID: 2515665 [TBL] [Abstract][Full Text] [Related]
4. Application of high-performance liquid chromatography for recognition of covalent nucleic acid modification with anticancer drugs. Cummings J; French RC; Smyth JF J Chromatogr; 1993 Aug; 618(1-2):251-76. PubMed ID: 8227259 [TBL] [Abstract][Full Text] [Related]
5. Characterization of covalent DNA binding of morpholino and cyanomorpholino derivatives of doxorubicin. Lau DH; Durán GE; Sikic BI J Natl Cancer Inst; 1992 Oct; 84(20):1587-92. PubMed ID: 1404452 [TBL] [Abstract][Full Text] [Related]
6. Crystal structure of epidoxorubicin-formaldehyde virtual crosslink of DNA and evidence for its formation in human breast-cancer cells. Podell ER; Harrington DJ; Taatjes DJ; Koch TH Acta Crystallogr D Biol Crystallogr; 1999 Sep; 55(Pt 9):1516-23. PubMed ID: 10489446 [TBL] [Abstract][Full Text] [Related]
7. A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues. Lucas AT; O'Neal SK; Santos CM; White TF; Zamboni WC J Pharm Biomed Anal; 2016 Feb; 119():122-9. PubMed ID: 26678179 [TBL] [Abstract][Full Text] [Related]
8. Metabolic activation of adriamycin by NADPH-cytochrome P450 reductase; overview of its biological and biochemical effects. Bartoszek A Acta Biochim Pol; 2002; 49(2):323-31. PubMed ID: 12362973 [TBL] [Abstract][Full Text] [Related]
9. The effect of the anthrapyrazole antitumour agent CI941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes. Inhibition of doxorubicin activation in vitro. Graham MA; Newell DR; Butler J; Hoey B; Patterson LH Biochem Pharmacol; 1987 Oct; 36(20):3345-51. PubMed ID: 2823819 [TBL] [Abstract][Full Text] [Related]
10. The interaction of nemorubicin metabolite PNU-159682 with DNA fragments d(CGTACG)(2), d(CGATCG)(2) and d(CGCGCG)(2) shows a strong but reversible binding to G:C base pairs. Mazzini S; Scaglioni L; Mondelli R; Caruso M; Sirtori FR Bioorg Med Chem; 2012 Dec; 20(24):6979-88. PubMed ID: 23154079 [TBL] [Abstract][Full Text] [Related]
11. Alkyl-Modified Oligonucleotides as Intercalating Vehicles for Doxorubicin Uptake via Albumin Binding. Purdie L; Alexander C; Spain SG; Magnusson JP Mol Pharm; 2018 Feb; 15(2):437-446. PubMed ID: 29265823 [TBL] [Abstract][Full Text] [Related]
12. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines. Taatjes DJ; Fenick DJ; Koch TH Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398 [TBL] [Abstract][Full Text] [Related]
13. Covalent binding of elliptinium acetate (NSC 264137) to nucleic acids of L1210 cells in culture. Dugue B; Auclair C; Meunier B Cancer Res; 1986 Aug; 46(8):3828-33. PubMed ID: 2425935 [TBL] [Abstract][Full Text] [Related]
15. A novel microplate-based HPLC-fluorescence assay for determination of NADPH-cytochrome P450 reductase activity. Erban T; Poltronieri P; Stara J Biomed Chromatogr; 2012 Sep; 26(9):1062-5. PubMed ID: 22120726 [TBL] [Abstract][Full Text] [Related]
16. Covalent coupling of doxorubicin in protein microspheres is a major determinant of tumour drug disposition. Cummings J; Willmott N; Marley E; Smyth J Biochem Pharmacol; 1991 Jun; 41(12):1849-54. PubMed ID: 2039540 [TBL] [Abstract][Full Text] [Related]
17. Metabolic activation of adriamycin by NADPH-cytochrome P-450 reductase, rat liver and heart microsomes and covalent protein binding of metabolites. Scheulen ME; Kappus H Adv Exp Med Biol; 1981; 136 Pt A():471-85. PubMed ID: 6807062 [No Abstract] [Full Text] [Related]
18. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach. Delaporte E; Slaughter DE; Egan MA; Gatto GJ; Santos A; Shelley J; Price E; Howells L; Dean DC; Rodrigues AD J Biomol Screen; 2001 Aug; 6(4):225-31. PubMed ID: 11689122 [TBL] [Abstract][Full Text] [Related]
19. Rapid high throughput assay for fluorimetric detection of doxorubicin--application of nucleic acid-dye bioprobe. Liu Y; Danielsson B Anal Chim Acta; 2007 Mar; 587(1):47-51. PubMed ID: 17386752 [TBL] [Abstract][Full Text] [Related]
20. Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF). Herzig MC; Arnett B; MacDonald JR; Woynarowski JM Biochem Pharmacol; 1999 Jul; 58(2):217-25. PubMed ID: 10423161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]